(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for Mountain Objections on the planet - 2Vietnam rethinks its flood strategy as climate change drives storms and devastation
- 34 Jeep Models: Dominating Execution and Flexibility for Each Experience
- 4The most effective method to Recognize a Great Lab Jewel
- 5Grasping the Course of Evacuation and Extradition in U.S. Migration
- India's top court hears challenges to ruling on women's entry into temple
- Polish law aimed at lowering petrol prices takes effect
- Surprising links between autism, Alzheimer’s could change how we treat both
- Man triggers smoke bomb during failed crypto robbery
- Bahrain cracks down on dissent as war grinds on
- Israel Police arrest twenty-one as anti-war protests grow despite broad support for Iran war
- Ukraine to get up to 100 French-made Rafale fighter jets
- 5 Instructive Toy Brands for Youngsters
- Instructions to Expand Your Advantages from an Open Record Reward
